CRDL - Cardiol Therapeutics Inc.
IEX Last Trade
1.32
0.070 5.303%
Share volume: 1,001
Last Updated: Thu 26 Dec 2024 04:30:34 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.82%
PREVIOUS CLOSE
CHG
CHG%
$1.25
0.07
5.60%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.56%
1 Month
-18.18%
3 Months
-40.57%
6 Months
-40.57%
1 Year
50.90%
2 Year
140.00%
Key data
Stock price
$1.32
DAY RANGE
$1.25 - $1.25
52 WEEK RANGE
$0.86 - $3.12
52 WEEK CHANGE
$51.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: David G. Elsley
Region: US
Website: cardiolrx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cardiolrx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cardiol Therapeutics Inc. focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD) Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability.
Recent news